COVID-19 increases age- and sex-controlled 21-day fatality rates for patients with melanoma, hematologic malignancies, uterine cancer, or kidney cancer
View ORCID ProfileHaiquan Li, Edwin Baldwin, Xiang Zhang, Colleen Kenost, Wenting Luo, Elizabeth A. Calhoun, Lingling An, Charles L. Bennett, Yves A. Lussier
doi: https://doi.org/10.1101/2021.02.06.21251099
Haiquan Li
1Department of Biosystems Engineering, University of Arizona, Tucson, Arizona
PhDEdwin Baldwin
1Department of Biosystems Engineering, University of Arizona, Tucson, Arizona
BSXiang Zhang
1Department of Biosystems Engineering, University of Arizona, Tucson, Arizona
MSColleen Kenost
4Cancer Center and Department of Medicine, University of Arizona, Tucson, Arizona
EdD, MPHWenting Luo
1Department of Biosystems Engineering, University of Arizona, Tucson, Arizona
MSElizabeth A. Calhoun
2Department of Population Health, University of Kansas Medical Center, Westwood, Kansas
PhDLingling An
1Department of Biosystems Engineering, University of Arizona, Tucson, Arizona
PhDCharles L. Bennett
3Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia, South Carolina
MD, PhDYves A. Lussier
4Cancer Center and Department of Medicine, University of Arizona, Tucson, Arizona
MD![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
The results will be shared upon request. The original data was from UK Biobank so the access should follow UK Biobank data access application process.
Posted February 08, 2021.
COVID-19 increases age- and sex-controlled 21-day fatality rates for patients with melanoma, hematologic malignancies, uterine cancer, or kidney cancer
Haiquan Li, Edwin Baldwin, Xiang Zhang, Colleen Kenost, Wenting Luo, Elizabeth A. Calhoun, Lingling An, Charles L. Bennett, Yves A. Lussier
medRxiv 2021.02.06.21251099; doi: https://doi.org/10.1101/2021.02.06.21251099
COVID-19 increases age- and sex-controlled 21-day fatality rates for patients with melanoma, hematologic malignancies, uterine cancer, or kidney cancer
Haiquan Li, Edwin Baldwin, Xiang Zhang, Colleen Kenost, Wenting Luo, Elizabeth A. Calhoun, Lingling An, Charles L. Bennett, Yves A. Lussier
medRxiv 2021.02.06.21251099; doi: https://doi.org/10.1101/2021.02.06.21251099
Subject Area
Subject Areas
- Addiction Medicine (347)
- Allergy and Immunology (666)
- Anesthesia (181)
- Cardiovascular Medicine (2637)
- Dermatology (223)
- Emergency Medicine (398)
- Epidemiology (12211)
- Forensic Medicine (10)
- Gastroenterology (758)
- Genetic and Genomic Medicine (4087)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2646)
- Health Policy (1003)
- Hematology (362)
- HIV/AIDS (850)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (433)
- Neurology (3862)
- Nursing (209)
- Nutrition (577)
- Oncology (2022)
- Ophthalmology (584)
- Orthopedics (240)
- Otolaryngology (304)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (472)
- Pediatrics (1113)
- Primary Care Research (450)
- Public and Global Health (6516)
- Radiology and Imaging (1398)
- Respiratory Medicine (871)
- Rheumatology (404)
- Sports Medicine (342)
- Surgery (444)
- Toxicology (52)
- Transplantation (185)
- Urology (165)